Looks back at how infusion doses of a skin-delivered drug change in Parkinson's disease
Reviews past records of a drug given under the skin in advanced Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Key facts
- Where
- Graz, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at adults with advanced Parkinson's disease who were prescribed foslevodopa/foscarbidopa by subcutaneous infusion in routine care and joined the AbbVie Patient Support Program.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Advanced Parkinson's disease that responds to levodopa (idiopathic Parkinson's disease)
- Earlier treatment
- Prescribed foslevodopa/foscarbidopa (LDp/CDp) subcutaneous infusion in routine clinical practice
Read by machine on 9 November 2026.
Where in Austria
- Medizinische Universitaet Graz /ID# 278569Graz, AustriaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06937034
- Record updated
- 5 August 2025
- Original description
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.Read full original descriptionShow less
Observational Retrospective CoHort Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Inclusion: Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.